Heartflow, Inc. Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
Heartflow (NASDAQ: HTFL), an AI technology company focused on coronary artery disease (CAD), has successfully completed its upsized Initial Public Offering (IPO). The company sold 19,166,667 shares at $19 per share, including the full exercise of the underwriters' option to purchase additional 2,500,000 shares.
The IPO generated total gross proceeds of approximately $364.2 million before deducting underwriting discounts and other expenses. Trading of Heartflow's common stock began on the Nasdaq Global Select Market on August 8, 2025. The offering was jointly managed by J.P. Morgan, Morgan Stanley, and Piper Sandler, with Stifel and Canaccord Genuity acting as co-managers.
Heartflow (NASDAQ: HTFL), azienda tecnologica specializzata nell'intelligenza artificiale per la malattia coronarica (CAD), ha completato con successo l'IPO aumentata. La società ha venduto 19,166,667 azioni a $19 per azione, inclusa la piena esercitazione dell'opzione dei sottoscrittori per acquistare ulteriori 2,500,000 azioni.
L'IPO ha generato proventi lordi complessivi di circa $364.2 million prima degli sconti per la sottoscrizione e di altre spese. Le azioni ordinarie di Heartflow hanno iniziato a essere negoziate sul Nasdaq Global Select Market l'8 agosto 2025. L'offerta è stata gestita congiuntamente da J.P. Morgan, Morgan Stanley e Piper Sandler, con Stifel e Canaccord Genuity in qualità di co-manager.
Heartflow (NASDAQ: HTFL), empresa de tecnología de IA centrada en la enfermedad de las arterias coronarias (CAD), ha completado con éxito su OPI ampliada. La compañía vendió 19,166,667 acciones a $19 por acción, incluyendo el ejercicio íntegro de la opción de los colocadores para comprar 2,500,000 acciones adicionales.
La OPI generó unos ingresos brutos totales de aproximadamente $364.2 million antes de descontar comisiones de suscripción y otros gastos. Las acciones ordinarias de Heartflow comenzaron a cotizar en el Nasdaq Global Select Market el 8 de agosto de 2025. La oferta fue gestionada conjuntamente por J.P. Morgan, Morgan Stanley y Piper Sandler, con Stifel y Canaccord Genuity como co-gestores.
Heartflow (NASDAQ: HTFL)는 관상동맥질환(CAD)에 주력하는 인공지능(AI) 기술 기업으로, 증액된 기업공개(IPO)를 성공적으로 마무리했습니다. 회사는 19,166,667주를 주당 $19에 매각했으며, 인수단의 추가 2,500,000주 매입 옵션을 전부 행사했습니다.
이번 IPO로 인수수수료 및 기타 비용을 공제하기 전 약 $364.2 million의 총 공모금액을 조달했습니다. Heartflow의 보통주는 2025년 8월 8일부터 나스닥 글로벌 셀렉트 마켓에서 거래를 시작했습니다. 공모는 J.P. Morgan, Morgan Stanley, Piper Sandler가 공동 주관했으며 Stifel과 Canaccord Genuity가 공동 인수역을 맡았습니다.
Heartflow (NASDAQ: HTFL), entreprise technologique spécialisée dans l'intelligence artificielle pour la maladie coronarienne (CAD), a clôturé avec succès son introduction en bourse (IPO) augmentée. La société a vendu 19,166,667 actions à $19 par action, incluant l'exercice intégral de l'option des souscripteurs d'acheter 2,500,000 actions supplémentaires.
L'IPO a généré des produits bruts d'environ $364.2 million avant déduction des commissions de placement et autres frais. Les actions ordinaires de Heartflow ont commencé à être négociées sur le Nasdaq Global Select Market le 8 août 2025. L'opération a été co-dirigée par J.P. Morgan, Morgan Stanley et Piper Sandler, avec Stifel et Canaccord Genuity comme co-gestionnaires.
Heartflow (NASDAQ: HTFL), ein auf koronare Herzkrankheit (CAD) fokussiertes KI-Technologieunternehmen, hat sein aufgestocktes IPO erfolgreich abgeschlossen. Das Unternehmen verkaufte 19,166,667 Aktien zu $19 je Aktie, einschließlich der vollständigen Ausübung der Option der Konsortialführer zum Kauf weiterer 2,500,000 Aktien.
Das IPO erzielte vor Abzug von Zeichnervergütungen und anderen Kosten Bruttoerlöse von rund $364.2 million. Der Handel mit den Stammaktien von Heartflow begann am 8. August 2025 am Nasdaq Global Select Market. Das Angebot wurde gemeinsam von J.P. Morgan, Morgan Stanley und Piper Sandler geleitet; Stifel und Canaccord Genuity fungierten als Co-Manager.
- Successfully raised $364.2 million in gross proceeds from IPO
- Achieved upsized offering with full exercise of underwriters' option
- Listed on the prestigious Nasdaq Global Select Market
- Strong backing from major investment banks as underwriters
- Potential dilution for early investors due to large share offering
- Significant offering expenses and underwriting discounts to be deducted from proceeds
Insights
Heartflow's $364.2M IPO demonstrates strong demand for AI healthcare companies with upsized offering and fully exercised greenshoe option.
Heartflow's IPO shows notable investor enthusiasm, evidenced by multiple positive signals. The company not only upsized its initial offering but also saw underwriters exercise their full option to purchase additional shares, indicating strong demand. The total raise of
The pricing at
The involvement of top-tier underwriters including J.P. Morgan, Morgan Stanley, and Piper Sandler as joint book-runners, with Stifel and Canaccord Genuity as co-managers, signals institutional confidence in Heartflow's business model and growth potential. The listing on Nasdaq's Global Select Market—Nasdaq's highest listing tier with the most stringent requirements—further validates the company's standing.
For the broader market, this successful IPO suggests ongoing appetite for healthcare technology companies with AI capabilities, particularly those addressing significant medical conditions like coronary artery disease, which remains a leading cause of mortality worldwide.
MOUNTAIN VIEW, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), a leader in AI technology for coronary artery disease (CAD), today announced the closing of its upsized initial public offering of 19,166,667 shares of its common stock at a public offering price of
J.P. Morgan, Morgan Stanley and Piper Sandler acted as joint book-running managers for the offering. Stifel and Canaccord Genuity acted as co-managers for the offering.
A registration statement relating to the shares sold in this offering was filed with, and declared effective by, the U.S. Securities and Exchange Commission. The offering was made only by means of a prospectus, copies of which may be obtained from J.P. Morgan, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; Morgan Stanley, 180 Varick Street, 2nd Floor, New York, NY 10014, Attention: Prospectus Department, or by email at prospectus@morganstanley.com; or Piper Sandler & Co., Attention: Prospectus Department, 350 North 5th Street, Suite 1300, Minneapolis, MN 55402, by telephone at (800) 747-3924 or by email at prospectus@psc.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Heartflow, Inc.
Heartflow is advancing coronary care by transforming coronary artery disease into a screenable, diagnosable, and manageable condition. Heartflow One is the only complete, non-invasive, precision coronary care platform providing patient insights throughout the guideline-directed CCTA pathway. The AI-driven platform — including Roadmap™ Analysis, FFRCT Analysis and Plaque Analysis — is supported by the ACC/AHA Chest Pain Guideline and backed by more than 600 peer-reviewed publications. Heartflow has helped clinicians manage over 400,000 patients worldwide.
Media Contact
Elliot Levy
elevy@heartflow.com
Investor Contact
Nick Laudico
nlaudico@heartflow.com
FAQ
How much money did Heartflow (HTFL) raise in its IPO?
What was the IPO price for Heartflow (HTFL) stock?
When did Heartflow (HTFL) start trading on Nasdaq?
How many shares did Heartflow (HTFL) sell in its IPO?
Who were the lead underwriters for Heartflow's IPO?
